Decreases in the expression of the surface targets CD30 and HER2 have been reported in lymphoma cell lines resistant to brentuximab vedotin (BV) [22] and breast cancer cell lines resistant to an analogue of T-DM1, respectively [23]. The gene discussed is ERBB2; the disease is breast carcinoma.